Menu
image description

Tag: Stelara

ACR|ARHP News on Potential New Lupus Treatments

The Lupus Research Alliance was on the ground at the American College of Rheumatology 2018 meeting to bring you the latest news in lupus research and translation.  Several clinical trials showed benefits of potential new treatments for helping people with lupus. Following are summaries of the stand-out results: Ustekinumab (Stelara®) A Phase 2 controlled study compared […] Read More

STELARA® Shows Positive Results

STELARA® (Ustekinumab) Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial   60 percent of patients receiving STELARA® showed significant reductions in lupus disease activity vs. 31 percent of patients receiving placebo STELARA® showed significant improvements in various disease measures compared with placebo, including musculoskeletal, mucocutaneous, immunological markers and flares Janssen […] Read More

Lupus Research Alliance Prompted Stelara® Study for Lupus

Lupus Research Alliance welcomes compelling new data, presented at the American College of Rheumatology (ACR) annual meeting that demonstrated significant benefit for lupus patients treated with Stelara® (ustekinumab), a prescription medicine from the Janssen Pharmaceutical Companies. Stelara® is not approved for the treatment of lupus, but is approved by the FDA for certain autoimmune diseases. Through its drug repurposing program, the Lupus Research Alliance first identified Stelara® as a potential treatment for lupus and encouraged Janssen to pursue testing for this use. Read More

because the Lupus Research Alliance board of directors funds all administrative and fundraising costs